Patents Assigned to BioArctic Neuroscience AB
-
Patent number: 9895234Abstract: A spinal cord device comprises a body formed of a biocompatible, biodegradable matrix. The body includes proximal, cranial and distal, caudal surfaces for connection to two ends of an injured spinal cord after removal of an injured section and has through channels with openings in the cranial and caudal surfaces for connection of descending motor pathways and ascending sensory pathways. The device has a transversal diameter (Dt), an anteroposterior diameter (Da) and a length (L), wherein Dt is from 9 to 13 mm and the ratio anteroposterior diameter/transverse diameter (RAPT) is from 0.5 to 1.0 and wherein the position and dimension of the channels, RAPT value, and cranial surface area and/or caudal surface area of the device are adopted to the shape, level, dimension of white and gray matter, and size of the injured spinal cord for optimal connection between spinal cord tracts. Kits and methods employ such devices.Type: GrantFiled: December 3, 2012Date of Patent: February 20, 2018Assignee: BIOARCTIC NEUROSCIENCE ABInventors: Arvid Frostell, Per Mattsson, Mikael Svensson
-
Patent number: 9573994Abstract: The present invention relates to the amyloid beta peptide (A?) and more specifically to antibodies binding to A? protofibrils and their use in therapy and/or prophylactic treatment of Alzheimer's disease and other disorders associated with A? protein aggregation. Further the invention may relate to diagnosis of such diseases as well as monitoring of disease progression by use of the antibodies of the invention. Further, the invention may relate to veterinary use of the antibodies of the invention.Type: GrantFiled: July 8, 2015Date of Patent: February 21, 2017Assignees: BioArctic Neuroscience AB, Eisai R&D Management Co., Ltd.Inventors: Charlotte Nerelius, Hanna Laudon, Jessica Sigvardson
-
Patent number: 9315569Abstract: Methods of treating or delaying onset of a neurodegenerative disorder with ?-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble ?-synuclein oligomer and capable of binding a stabilized soluble ?-synuclein oligomer, the stabilized soluble ?-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the ?-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble ?-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with ?-synuclein pathology is characterized by deposition of Lewy bodies and Lewy neurites or is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease, and multiple system atrophy (MSA).Type: GrantFiled: July 21, 2014Date of Patent: April 19, 2016Assignee: BioArctic Neuroscience ABInventors: Lars Lannfelt, Joakim Bergström, Martin Ingelsson, Pär Gellerfors
-
Patent number: 9084832Abstract: In an in vivo method for detecting ?-synuclein protofibrils in human tissue, an antibody or fragment thereof is administered to a human. The antibody or fragment is labelled with a detectable label. A complex formed between the antibody or fragment and ?-synuclein protofibrils in the human tissue is detected. The antibody or fragment has high affinity for human ?-synuclein protofibrils and low affinity for ?-synuclein monomers and has a combination of three specified variable heavy (VH) CDR sequences and three specified variable light (VL) CDR sequences.Type: GrantFiled: February 2, 2015Date of Patent: July 21, 2015Assignee: BioArctic Neuroscience ABInventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
-
Patent number: 9034334Abstract: The invention relates to an isolated antibody, or fragment thereof, having high affinity for human A? protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which includes the step of administering to a patient having or suspected of having Alzheimer's disease such an antibody, or fragment thereof or a composition that includes the antibody or a fragment thereof.Type: GrantFiled: August 26, 2011Date of Patent: May 19, 2015Assignee: BioArctic Neuroscience ABInventors: Pär Gellerfors, Lars Lannfelt, Dag Sehlin, Frida Ekholm Pettersson, Hillevi Englund
-
Patent number: 8999936Abstract: The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A? 42/40 protofibril comprising N-terminal truncated A? forms and (ii) A? 42/40 Arc protofibril comprising N-terminal truncated A? forms and (b) has no or little cross-reactivity to A? 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimer's disease.Type: GrantFiled: February 28, 2013Date of Patent: April 7, 2015Assignee: BioArctic Neuroscience ABInventors: Pär Gellerfors, Lars Lannfelt
-
Patent number: 8968734Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.Type: GrantFiled: August 28, 2014Date of Patent: March 3, 2015Assignee: BioArctic Neuroscience ABInventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
-
Patent number: 8859501Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.Type: GrantFiled: August 1, 2013Date of Patent: October 14, 2014Assignee: BioArctic Neuroscience ABInventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
-
Patent number: 8809506Abstract: A vaccine for delaying an onset of or for treatment of an ?-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble ?-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the ?-synuclein. An antibody for delaying an onset of or for treatment of an ?-synuclein-related disorder in an individual binds soluble ?-synuclein. Methods for delaying an onset of for treatment or for prevention of an ?-synuclein-related disorder employ the vaccine or antibody. Methods of detecting ?-synuclein oligomers employ the antibody.Type: GrantFiled: April 28, 2009Date of Patent: August 19, 2014Assignee: BioArctic Neuroscience ABInventors: Lars Lannfelt, Joakim Bergström, Martin Ingelsson, Pär Gellerfors
-
Patent number: 8632776Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.Type: GrantFiled: February 25, 2011Date of Patent: January 21, 2014Assignee: BioArctic Neuroscience ABInventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
-
Publication number: 20130309251Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.Type: ApplicationFiled: August 1, 2013Publication date: November 21, 2013Applicant: BIOARCTIC NEUROSCIENCE ABInventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
-
Publication number: 20130236452Abstract: The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A? 42/40 protofibril comprising N-terminal truncated A? forms and (ii) A? 42/40 Arc protofibril comprising N-terminal truncated A? forms and (b) has no or little cross-reactivity to A? 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimer's disease.Type: ApplicationFiled: February 28, 2013Publication date: September 12, 2013Applicant: BioArctic Neuroscience ABInventors: Pär Gellerfors, Lars Lannfelt
-
Patent number: 8409575Abstract: The invention relates to a purified antibody or fragment thereof that specifically binds an A? protofibril. The invention further relates to a composition that includes such antibodies. The invention also relates to using such antibodies and compositions for treating a patient having of suspected of having Alzheimer's disease.Type: GrantFiled: August 26, 2011Date of Patent: April 2, 2013Assignee: BioArctic Neuroscience ABInventors: Lars Lannfelt, Camilla Nilsberth, Anita Campbell, Jan Näslund
-
Patent number: 8404459Abstract: The invention pertains to a method of measuring A? protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype A? 42/40 protofibril and A?42/40 Arc protofibril and has no or little cross-reactivity to A? 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising A? protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.Type: GrantFiled: December 23, 2011Date of Patent: March 26, 2013Assignee: BioArctic Neuroscience ABInventors: Pär Gellerfors, Lars Lannfelt
-
Publication number: 20120308572Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.Type: ApplicationFiled: February 25, 2011Publication date: December 6, 2012Applicant: BioArctic Neuroscience ABInventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
-
Publication number: 20120230912Abstract: The invention pertains to a method of measuring A? protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype A? 42/40 protofibril and A?42/40 Arc protofibril and has no or little cross-reactivity to A? 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising A? protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.Type: ApplicationFiled: December 23, 2011Publication date: September 13, 2012Applicant: BioArctic Neuroscience ABInventors: Pär Gellerfors, Lars Lannfelt
-
Publication number: 20120156222Abstract: The present invention relates to a purified antibody that specifically binds an ?-synuclein protofibril.Type: ApplicationFiled: March 5, 2012Publication date: June 21, 2012Applicant: BIOARCTIC NEUROSCIENCE ABInventor: LARS LANNFELT
-
Publication number: 20120076726Abstract: The invention relates to an isolated antibody, or fragment thereof, having high affinity for human A? protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which includes the step of administering to a patient having or suspected of having Alzheimer's disease such an antibody, or fragment thereof or a composition that includes the antibody or a fragment thereof.Type: ApplicationFiled: August 26, 2011Publication date: March 29, 2012Applicant: BIOARCTIC NEUROSCIENCE ABInventors: Par GELLERFORS, Lars LANNFELT, Dag SEHLIN, Frida EKHOLM PETTERSSON, Hillevi ENGLUND
-
Patent number: 8106164Abstract: The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils.Type: GrantFiled: June 21, 2005Date of Patent: January 31, 2012Assignee: BioArctic Neuroscience ABInventors: Pär Gellerfors, Lars Lannfelt
-
Patent number: 8025878Abstract: The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (A?) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(C1q) binding, effective in clearance of A? protofibrils and with reduce risk of inflammation.Type: GrantFiled: March 23, 2007Date of Patent: September 27, 2011Assignee: BioArctic Neuroscience ABInventors: Pär Gellerfors, Lars Lannfelt, Dag Sehlin, Frida Ekholm Pettersson, Hillevi Englund